Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…
Sponsor: AstraZeneca
NCT ID: NCT06921785
Sites in New Jersey: - Research Site — New Brunswick, New Jersey
Phase 3 Recruiting Academic/Other
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocar…
Sponsor: Georgetown University
NCT ID: NCT05482516
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…
Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in New Jersey: - MorristownMedicalCenter — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Rutgers Cancer Institute of New Jersey at University Hospital — Newark, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07291076
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 1, Phase 2 Recruiting Industry
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GP…
Sponsor: AstraZeneca
NCT ID: NCT06795022
Sites in New Jersey: - Research Site — Hackensack, New Jersey
Phase 2 Recruiting Academic/Other
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and i…
Sponsor: Rutgers, The State University of New Jersey
NCT ID: NCT05366829
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in New Jersey: - Exelixis Clinical Site #88 — East Brunswick, New Jersey
- Exelixis Clinical Site #105 — Hackensack, New Jersey
Phase 1 Recruiting Industry
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lun…
Sponsor: Zymeworks BC Inc.
NCT ID: NCT07164313
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in New Jersey: - Massive Bio SYNERGY-AI site — New Brunswick, New Jersey
Recruiting Industry
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
Sponsor: Elephas
NCT ID: NCT05520099
Sites in New Jersey: - John Theurer Cancer Center — Hackensack, New Jersey
NA Recruiting Academic/Other
the investigators will pursue two specific aims: (1) to monitor the extent of heme oxygenase induction (by measuring endogenous CO production) in relationship to the extent of hepatic resection (2) to assess the production of CO in patient…
Sponsor: Englewood Hospital and Medical Center
NCT ID: NCT06681818
Sites in New Jersey: - Englewood Hospital — Englewood, New Jersey